New drug combo targets tough blood cancers

NCT ID NCT07032727

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinations are. About 68 adults will take part at M.D. Anderson Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olutasidenib (taken by mouth) combined with other drugs (cladribine, venetoclax, gilteritinib, ruxolitinib, or cytarabine) given by injection or mouth
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat blood cancers that have specific genetic mutations.
What could go wrong: This is an early phase 2 trial with only 68 participants, so results may not apply to everyone. Drug combinations can cause serious side effects, and the cancer may still return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic/myeloproliferative neoplasm myeloid neoplasm myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDH1-MUTATED MALIGNANCIES MUTATIONS TARGETED THERAPY

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.